Souvenaid
Oral medical food containing the Fortasyn Connect multi-nutrient formulation and marketed for use under medical supervision in people with early Alzheimer's disease. Randomized-trial synthesis has not shown a convincing effect on progression to dementia or most patient-important cognitive and functional outcomes.
Pharmacokinetic model
A route-level PK model for souvenaid is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- Medical Food
- Suggested cadence
- once daily
Research behind this entry
-
Souvenaid for Alzheimer's disease
Cochrane review included three randomized placebo-controlled trials with 1,097 participants. Moderate-certainty evidence found little or no effect on progression to dementia, cognition, or everyday function; a small…
-
The effects of omega-3, DHA, EPA, Souvenaid in Alzheimer's disease: A systematic review and meta-analysis
Review pooled 14 heterogeneous studies of several omega-3 interventions and Souvenaid. It reported less decline on the CDR scale, but no significant differences for MMSE, ADAS-cog, activities of daily living, adverse…
-
Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial.
This citation reports a human clinical study involving Souvenaid. It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.
3 published studies referenced in the app, each with a plain-language summary.